← The Wire
BCAXNasdaq
Bicara Therapeutics Inc.
Pharmaceutical Preparations · DE · CIK 2023658
Bicara Therapeutics develops bifunctional therapies targeting solid tumors by delivering payloads to tumor sites
$1.43B
Market cap
$29.34
Last close
+9.2%
1D
+19.5%
5D
1.6M
Volume
Price · last 39 sessions+29.1%
May 4L $19.29 · H $29.34Jun 29
41
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 10, 20268-KCompany UpdateMay 21, 202610-Q10-QMay 11, 20268-KResults of OperationsMay 11, 2026DEFA14ADEFA14AApr 27, 2026DEF 14ADEF 14AApr 27, 202610-K10-KMar 30, 20268-KResults of OperationsMar 30, 2026SC 13D/ASC 13D/AMar 2, 20268-KMaterial Agreement · Results of OperationsFeb 26, 2026424B5424B5Feb 26, 2026424B5424B5Feb 24, 20268-KCompany UpdateFeb 19, 20268-KCompany UpdateJan 12, 20268-KReg FD Disclosure · Company UpdateDec 8, 2025424B5424B5Nov 26, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KShareholder VoteJun 12, 20258-KMaterial AgreementJun 6, 202510-Q10-QMay 13, 20258-KResults of OperationsMay 13, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 202510-K10-KMar 27, 20258-KResults of OperationsMar 27, 20258-KReg FD DisclosureJan 13, 202510-Q10-QNov 12, 20248-KResults of Operations · Reg FD DisclosureNov 12, 2024SC 13GSC 13GSep 26, 2024SC 13GSC 13GSep 26, 2024SC 13DSC 13DSep 23, 2024SC 13DSCHEDULE TO REPORT BENEFICIAL OWNERSHIP OF 5% OR MORESep 18, 2024SC 13GSC 13GSep 18, 20248-KBylaw AmendmentSep 16, 2024424B4424B4Sep 13, 2024S-1/AS-1/ASep 11, 2024S-1/AS-1/ASep 6, 2024S-1/AS-1/ASep 3, 2024S-1S-1Aug 22, 2024
Insider Activity
In the 90 days to Mar 25, 2026: 1 insider bought $4.8M · 4 sold $2.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Raben DavidChief Medical Officer | Sell | 5,500 | $18.95 | $104K |
| Mar 23, 2026 | Hyep IvanChief Financial Officer | Sell | 9,200 | $18.52 | $170K |
| Mar 20, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 1,596 | $18.95 | $30K |
| Mar 19, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 6,905 | $18.78 | $130K |
| Mar 18, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 6,499 | $18.84 | $122K |
| Mar 16, 2026 | Cohlhepp RyanPresident and COO | Sell | 8,000 | $19.66 | $157K |
| Mar 16, 2026 | Cohlhepp RyanPresident and COO | Sell | 4,500 | $19.66 | $88K |
| Mar 9, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 36,766 | $19.17 | $705K |
| Mar 6, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 3,817 | $18.75 | $72K |
| Mar 5, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 1,786 | $18.74 | $33K |
| Mar 4, 2026 | Raben DavidChief Medical Officer | Sell | 16,300 | $18.52 | $302K |
| Mar 4, 2026 | Hyep IvanChief Financial Officer | Sell | 2,963 | $18.25 | $54K |
| Mar 4, 2026 | Mazumdar ClaireChief Executive Officer | Sell | 2,631 | $18.73 | $49K |
| Mar 3, 2026 | Hyep IvanChief Financial Officer | Sell | 13,555 | $18.22 | $247K |
| Mar 3, 2026 | Cohlhepp RyanPresident and COO | Sell | 12,892 | $18.16 | $234K |
| Mar 3, 2026 | Cohlhepp RyanPresident and COO | Sell | 4,500 | $18.16 | $82K |
| Mar 3, 2026 | Raben DavidChief Medical Officer | Sell | 200 | $18.45 | $4K |
| Feb 26, 2026 | Ra Capital Management, L.P.Director,TenPercentOwner | Buy | 300,000 | $16.00 | $4.8M |
| Feb 25, 2026 | Cohlhepp RyanPresident and COO | Sell | 3,108 | $18.04 | $56K |
| Feb 25, 2026 | Cohlhepp RyanPresident and COO | Sell | 523 | $18.04 | $9K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance